DECIDUOUS THERAPEUTICS
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder.
DECIDUOUS THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Founded:
2018-01-01
Address:
San Francisco, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
650-206-9082
Total Funding:
6.5 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
BOA Nutrition
BOA Nutrition is a nutraceutical company based in North Carolina.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Janus Health
Janus is leapfrogging the low-code, no-code solutions of today by developing a vertically integrated process improvement platform.
Wavely Diagnostics
Wavely Diagnostics is a digital diagnostics company developing smartphone-based apps to bring accurate, data-driven virtual pediatric care.
Current Employees Featured
Founder
Investors List
Presight Capital
Presight Capital investment in Seed Round - Deciduous Therapeutics
8VC
8VC investment in Seed Round - Deciduous Therapeutics
Longevity Vision Fund
Longevity Vision Fund investment in Seed Round - Deciduous Therapeutics
CRV
CRV investment in Seed Round - Deciduous Therapeutics
More informations about "Deciduous Therapeutics"
Home - Deciduous Therapeutics Inc.
Deciduous Therapeutics aims to positively impact human health span through the development of novel medicines that activate the endogenous immune mechanism responsible for the elimination of senescent cells. Our Science. …See details»
Deciduous Therapeutics - Crunchbase Company Profile & Funding
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is …See details»
Deciduous Therapeutics Company Profile 2024: Valuation, Funding ...
Deciduous Therapeutics General Information Description. Developer of novel therapeutics designed for the treatment of age-related diseases. The company's novel molecules can …See details»
Deciduous Therapeutics - LinkedIn
Deciduous Therapeutics Biotechnology Research San Francisco, California 2,736 followers Deciduous is developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.See details»
Deciduous Therapeutics - Funding, Financials, Valuation & Investors
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ...See details»
Restoring immune surveillance to tackle age-related …
Deciduous Therapeutics was founded when Regis Kelly, director of the California Institute for Quantitative Biosciences (QB3) at UCSF, introduced Bhushan to life sciences entrepreneur, Robin ...See details»
Deciduous Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore Deciduous Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 news, and 1 literature.See details»
Deciduous Therapeutics - VentureRadar
Deciduous Therapeutics is a biotechnology firm specializing in the development of innovative treatments for age-related diseases. Their groundbreaking approach involves the discovery of …See details»
Deciduous Therapeutics - VentureRadar
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies to promote healthy lifespan. Senescent cells accumulate and play a …See details»
Deciduous Therapeutics is Powered by CRV
Https://cdn.prod.website-files.com/64c7a317aea92912392c0420/64e3db676190e8e5e4c897bb_3t-biosciences-logo.webpSee details»
News - Deciduous Therapeutics Inc.
Eisai Innovation, Inc. and MBC BioLabs are happy to announce Deciduous Therapeutics as the winner of their 2021 Golden Ticket Competition. Eisai Innovation, Inc.’s inaugural competition …See details»
Deciduous Therapeutics - Updates, News, Events, Signals & Triggers
Aug 31, 2023 Deciduous Therapeutics is focused on developing immune modulatory therapies, specifically through the activation of invariant natural killer T (iNKT) cells. Their research …See details»
Deciduous Therapeutics - Nature
Deciduous Therapeutics, explained, “rather than target a non-specific anti-apoptotic pathway on senescent cells, Deciduous is focused on directly restoring the body’s natural immune …See details»
Deciduous Therapeutics Announces Appointments to the Board
Oct 27, 2021 Deciduous Therapeutics is an early stage, venture-backed biotech company based in San Francisco. The company is developing multiple activation approaches to clearing …See details»
Deciduous Therapeutics Announces Appointments to the Board, …
Oct 27, 2021 Deciduous Therapeutics is an early stage, venture-backed biotech company based in San Francisco. The company is developing multiple activation approaches to clearing …See details»
Attacking aging and chronic disease by eliminating 'senescent' …
May 10, 2021 Senior author Anil Bhushan, Ph.D., a professor of medicine at UCSF, has now co-founded a company called Deciduous Therapeutics to translate the discovery into medicines …See details»
Harnessing the immune system to target cellular senescence
May 11, 2021 Californian start-up Deciduous Therapeutics has emerged from stealth mode following the publication of a new paper that reveals the science behind its approach to …See details»
Robin Mansukhani - CEO of Deciduous Therapeutics
Dec 17, 2022 In this episode of the Life Science Success Podcast my guest is Robin Mansukhani. Robin is the CEO of Deciduous Therapeutics, a venture backed startup …See details»
Can a rare immune cell offer the key to slowing down senescence?
May 11, 2021 Robin Mansukhani, Deciduous Therapeutics CEO (Deciduous) May 11, 2021 11:27 AM EDT. Startups. Can a rare immune cell offer the key to slowing down senescence? …See details»